Biotech | April 08, 2022
CDSCO approves Phase II/III trial of Akston Bio’s Covid vaccine candidate in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
As part of its on-going work to track variants, WHO's Technical Advisory Group on SARS-CoV-2 Virus Evolution (TAG-VE) discussed the latest evidence on the Omicron variant of concern
Funding to grow the insurance and digital therapeutics vertical in India
The KRIVIDA Novus RT-PCR kit can detect the Omicron variant, its sub-lineages, and the Delta variant in 45 minutes
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
